Loading…
PDSB
PDS Biotechnology Corp
NASDAQ· Healthcare· Biotechnology· CUSIP 70465T107
$0.21-3.21%Price as of Aug 29, 18:31 UTC · updated once a day, after the close
Key metrics
- Market cap
- $11.8M
- P/E
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.62
- ROE
- -543.97%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 1.55
- 52-week high
- $1.55
- 52-week low
- $0.20
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -93.4% over 5Y.
today you would have $53.50▼ -94.7%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 11 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $0.77 | $1.63 | $4.97 | $13.20 | $8.10 | $2.14 | $2.65 | $6.42 | $187.40 | $250.00 | $250.00 | |
| P/E | — | — | — | — | — | — | — | — | 5.6x | — | — |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| SNTISenti Biosciences Holdings, Inc. | $0.38 | — | 4.6x | — | -466.46% | $11.74M |
| ASBPAspire Biopharma Holdings, Inc. | $8.51 | — | 0.9x | — | -1032.14% | $11.94M |
| KPRXKiora Pharmaceuticals Inc | $2.62 | — | 0.8x | — | -56.37% | $11.59M |
| BLRXBioLineRx Ltd. | $2.60 |
About the company
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, Georgia Research Foundation, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.
- 21
- Princeton, United States
Company description provided by Yahoo Finance.